206761-92-4 Usage
General Description
4-(2,4,6-trifluorophenyl)-3-thiosemicarbazide, also known as TPSC, is an organofluorine compound with the chemical formula C7H5F3N4S. It is a thiosemicarbazide derivative that contains a trifluorophenyl group. TPSC is a versatile building block in organic synthesis and has been used as a ligand in metal-catalyzed reactions. It is also being studied for its potential biological activities, including its antiproliferative and antifungal properties. TPSC has shown promising results in experimental tests and is a subject of ongoing research for its potential applications in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 206761-92-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,6,7,6 and 1 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 206761-92:
(8*2)+(7*0)+(6*6)+(5*7)+(4*6)+(3*1)+(2*9)+(1*2)=134
134 % 10 = 4
So 206761-92-4 is a valid CAS Registry Number.
InChI:InChI=1/C7H6F3N3S/c8-3-1-4(9)6(5(10)2-3)12-7(14)13-11/h1-2H,11H2,(H2,12,13,14)
206761-92-4Relevant articles and documents
Synthesis and Antiproliferative Activity of New Thiosemicarboxamide Derivatives
Chen, Jun,Fang, Meijuan,Guo, Yafei,Hu, Hongyu,Hu, Sangsang,Sun, Ke,Wu, Jun,Xue, Yuhua
, (2021/11/09)
To discover new anticancer agents, two series of thiosemicarboxamide derivatives were synthesized and evaluated for their antiproliferative activity against human cancer cells in vitro. Most target compounds (especially 3f, 3g, and 3h) exhibit potent antiproliferative activity against HeLa cells. Importantly, compound 3h, bearing a 4-methylphenyl substituent at N position of thiourea moiety, has significant and broad-spectrum inhibitory activities against cancer cells (HepG2, HeLa, MDA-MB231, A875, and H460 cells) with low IC50 values (5.0 μM) and shows low toxicity to normal LO2 and MRC-5 cells. Further studies show that compound 3h exerts high inhibitory activity in cancer cells by inducing the G2/M-phase arrest of cancer cells. Collectively, this study presents compound 3h as a new entity for the development of cell cycle arrest inducers for the treatment of cancer.
